In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells - NCT00731705-46202 (Clinical Trial 235427)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy235427.aspx
|
** Please review additional "Nearby Studies" on right ----->
This is an archived study that is no longer available, if you
would like to find active studies please
search our studies.
|
|
 |
 |
|
| City: |
|
Indianapolis |
|
State:
|
|
IN |
| Zip Code: |
|
46202 |
| Conditions: |
|
Hematologic Malignancies - Hematopoietic Stem Cell Transplantation |
| Purpose: |
|
The doctors in the Bone Marrow Transplant Service at the Indiana University Cancer Center
are working to better understand how the immune cells that cause graft-versus-host disease
(a major complication of stem cell transplantation in which the donor immune cells attack
the patient's organs) can be selectively removed from the graft, leaving other immune cells
that fight infections.
|
| Study summary: |
|
The purpose of this research is to study how immune cells (called T cells) that cause
graft-versus-host disease (GVHD) can best be selectively separated from other T cells and
removed from the cells that will be returned to the cancer patient's body. These other T
cells may protect against infection when given to patients after a stem cell transplant.
The removal of cells that cause GVHD would allow doctors to safely give back the T cells
that protect against infection, without the risk of GVHD. |
| Criteria: |
|
Inclusion Criteria:
- Patients with hematological malignancies who are undergoing evaluation for autologous
or allogeneic stem cell transplants will be eligible, if: (1)They have no circulating
neoplastic cells in the peripheral blood as assessed by routine morphology or flow
cytometry. (2)Patients with acute myeloid or lymphocytic leukemia are in complete
remission
- First-degree relatives of patients evaluated for stem cell transplantation will be
eligible if: (1) Willing to undergo testing for HIV and hepatitis B and C (free of
charge) (2) Not pregnant at time of collection of blood (3)In good general health (4)
No prior history of malignancy. (5) Age 18 years or older if donating apheresis
product. (Because of the relatively invasive nature of the leukopheresis procedure
and difficulties in obtaining consent, children <18 who are first degree relatives of
the patient will not undergo apheresis for studies on this protocol)
- Written informed consent
Exclusion Criteria:
- |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 1, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|